Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Nov 2;5(4):237–248. doi: 10.1097/BS9.0000000000000173

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the Chinese Medical Association (CMA) and Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College (IHCAMS).

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — Where are we heading in the field of CAR-T? (A) New targets for CAR-T-cell therapy for B-cell leukemia/lymphoma, T-cell leukemia/lymphoma, AML, HL, MM, and solid tumors; (B) New design for CAR-T cell, utilizing suicide or logic-gated switches to improve their safety and controllability; (C) CAR-T cells in combination with immune checkpoint inhibitors, lysoviruses, or radiotherapy; (D) Next-generation CAR-Ts, including UCAR-T, CAR-NK, CAR-MΦ, and CAR-γδ T. AML = acute myeloid leukemia, CAR = chimeric antigen receptor, CAR-MΦ = CAR macrophages, HL = Hodgkin lymphoma, MM = multiple myeloma, NK = natural killer cell, UCAR-T = universal CAR-T.